• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia.

作者信息

Roeker Lindsey E, Knorr David A, Pessin Melissa S, Ramanathan Lakshmi V, Thompson Meghan C, Leslie Lori A, Zelenetz Andrew D, Mato Anthony R

机构信息

Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

Leukemia. 2020 Nov;34(11):3047-3049. doi: 10.1038/s41375-020-01030-2. Epub 2020 Aug 27.

DOI:10.1038/s41375-020-01030-2
PMID:32855439
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7450257/
Abstract
摘要

相似文献

1
Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者的抗严重急性呼吸综合征冠状病毒2抗体反应
Leukemia. 2020 Nov;34(11):3047-3049. doi: 10.1038/s41375-020-01030-2. Epub 2020 Aug 27.
2
Recovered COVID-19 patients with recurrent viral RNA exhibit lower levels of anti-RBD antibodies.新冠病毒核糖核酸（RNA）复发的康复新冠患者体内抗受体结合域（RBD）抗体水平较低。
Cell Mol Immunol. 2020 Oct;17(10):1098-1100. doi: 10.1038/s41423-020-00528-0. Epub 2020 Sep 16.
3
Mining of epitopes on spike protein of SARS-CoV-2 from COVID-19 patients.从新冠肺炎患者中挖掘严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白上的表位
Cell Res. 2020 Aug;30(8):702-704. doi: 10.1038/s41422-020-0366-x. Epub 2020 Jul 1.
4
Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection.新型冠状病毒血清中和抗体的持续时间：严重急性呼吸综合征冠状病毒感染的经验教训。
J Microbiol Immunol Infect. 2020 Oct;53(5):821-822. doi: 10.1016/j.jmii.2020.03.015. Epub 2020 Mar 25.
5
A COVID-19 Patient with Repeatedly Undetectable SARS-CoV-2 Antibodies.一名严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗体多次检测不到的新型冠状病毒肺炎（COVID-19）患者。
J Appl Lab Med. 2020 Nov 1;5(6):1401-1405. doi: 10.1093/jalm/jfaa137.
6
Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients.SARS-CoV-2 特异性抗体分泌细胞的扩增和住院 COVID-19 患者中中和抗体的产生。
J Immunol. 2020 Nov 1;205(9):2437-2446. doi: 10.4049/jimmunol.2000717. Epub 2020 Sep 2.
7
Evaluations of the serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak.新型冠状病毒（SARS-CoV-2）感染的血清学检测在 COVID-19 疫情期间的诊断评估。
Eur J Clin Microbiol Infect Dis. 2020 Dec;39(12):2271-2277. doi: 10.1007/s10096-020-03978-6. Epub 2020 Jul 17.
8
Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity.正交 SARS-CoV-2 血清学检测可用于监测低流行社区，并揭示持久的体液免疫。
Immunity. 2020 Nov 17;53(5):925-933.e4. doi: 10.1016/j.immuni.2020.10.004. Epub 2020 Oct 14.
9
Kinetic changes in virology, specific antibody response and imaging during the clinical course of COVID-19: a descriptive study.新型冠状病毒感染临床病程中的病毒学、特异性抗体反应和影像学变化：一项描述性研究。
BMC Infect Dis. 2020 Nov 10;20(1):818. doi: 10.1186/s12879-020-05549-8.
10
Distinct Early Serological Signatures Track with SARS-CoV-2 Survival.与 SARS-CoV-2 存活相关的早期血清学特征。
Immunity. 2020 Sep 15;53(3):524-532.e4. doi: 10.1016/j.immuni.2020.07.020. Epub 2020 Jul 30.

引用本文的文献

1
Factors Associated With Mortality in Leukemia and Lymphoma With COVID-19: A National Inpatient Sample Analysis (2020-2021).2019冠状病毒病相关白血病和淋巴瘤死亡率的相关因素：一项全国住院患者样本分析（2020 - 2021年）
Cureus. 2025 Jun 22;17(6):e86534. doi: 10.7759/cureus.86534. eCollection 2025 Jun.
2
Management of infections for patient treated with ibrutinib in clinical practice.临床实践中接受依鲁替尼治疗患者的感染管理
Front Oncol. 2024 Sep 10;14:1428464. doi: 10.3389/fonc.2024.1428464. eCollection 2024.
3
Outcomes of COVID-19 infection in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis.慢性淋巴细胞白血病患者感染新型冠状病毒肺炎的结局：一项系统评价和荟萃分析
Rev Assoc Med Bras (1992). 2024 Aug 16;70(8):e20240322. doi: 10.1590/1806-9282.20240322. eCollection 2024.
4
COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches.COVID-19 与贫血和血液系统恶性肿瘤患者：风险因素、临床指南和新兴治疗方法。
Cell Commun Signal. 2024 Feb 15;22(1):126. doi: 10.1186/s12964-023-01316-9.
5
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study.慢性淋巴细胞白血病患者在奥密克戎大流行期间对SARS-CoV-2疫苗的抗体反应及COVID-19易感性：一项多中心研究的两年随访
Cancers (Basel). 2023 May 30;15(11):2993. doi: 10.3390/cancers15112993.
6
Evaluation of Antibody Responses in Patients with B-Cell Malignancies after Two and Three Doses of Anti-SARS-CoV-2 S Vaccination-A Retrospective Cohort Study.两剂和三剂抗SARS-CoV-2 S疫苗接种后B细胞恶性肿瘤患者抗体反应的评估——一项回顾性队列研究
Cancers (Basel). 2023 Jan 14;15(2):524. doi: 10.3390/cancers15020524.
7
Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review.免疫功能低下患者中持续的SARS-CoV-2感染促进病毒快速进化：回顾性队列研究与文献综述
Clin Infect Pract. 2022 Nov;16:100210. doi: 10.1016/j.clinpr.2022.100210. Epub 2022 Nov 16.
8
Predictors of clinical evolution of SARS-CoV-2 infection in hematological patients: A systematic review and meta-analysis.预测 SARS-CoV-2 感染在血液病患者中的临床演变的因素：系统评价和荟萃分析。
Hematol Oncol. 2023 Feb;41(1):16-25. doi: 10.1002/hon.3084. Epub 2022 Oct 20.
9
Cellular and humoral response to the fourth BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL.慢性淋巴细胞白血病患者接种第四剂 BNT162b2 mRNA COVID-19 疫苗后的细胞和体液反应。
Eur J Haematol. 2023 Jan;110(1):99-108. doi: 10.1111/ejh.13878. Epub 2022 Oct 23.
10
Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion.在 CLL 和 MBL 患者中接种多次 COVID-19 疫苗可提高免疫应答，具有渐进性和高血清转化率。
Blood. 2022 Dec 22;140(25):2709-2721. doi: 10.1182/blood.2022017814.

本文引用的文献

1
Effects of Human Behavior Changes During the Coronavirus Disease 2019 (COVID-19) Pandemic on Influenza Spread in Hong Kong.《2019 冠状病毒病（COVID-19）大流行期间人类行为变化对香港流感传播的影响》
Clin Infect Dis. 2021 Sep 7;73(5):e1142-e1150. doi: 10.1093/cid/ciaa1818.
2
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.SARS-CoV-2 mRNA-1273疫苗接种后反应的持久性。
N Engl J Med. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3.
3
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.在不耐受 BTK 或 PI3Kδ 抑制剂治疗的 CLL 患者中，评估 umbralisib 安全性和疗效的 2 期研究。
Blood. 2021 May 20;137(20):2817-2826. doi: 10.1182/blood.2020007376.
4
Development, performance evaluation, and clinical application of a Rapid SARS-CoV-2 IgM and IgG Test Kit based on automated fluorescence immunoassay.基于自动化荧光免疫分析的快速 SARS-CoV-2 IgM 和 IgG 检测试剂盒的开发、性能评估和临床应用。
J Med Virol. 2021 May;93(5):2838-2847. doi: 10.1002/jmv.26696. Epub 2021 Mar 1.
5
Mandatory mask-wearing policy and universal anti-viral treatment mitigate influenza outbreaks during the COVID-19 pandemic.强制佩戴口罩政策和普遍抗病毒治疗可减轻新冠疫情期间的流感暴发。
J Microbiol Immunol Infect. 2021 Feb;54(1):117-119. doi: 10.1016/j.jmii.2020.10.007. Epub 2020 Nov 7.
6
Reply to "CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report" Analysis of six hematological centers in Lombardy : On behalf of CLL commission of Lombardy Hematology Network (REL).对《巴塞罗那医院诊所的慢性淋巴细胞白血病与2019冠状病毒病：中期报告》的回复 伦巴第六个血液学中心的分析：代表伦巴第血液学网络慢性淋巴细胞白血病委员会（REL）
Leukemia. 2020 Sep;34(9):2531-2532. doi: 10.1038/s41375-020-0966-y. Epub 2020 Aug 4.
7
Perspective of a Physician Who Tested Persistently Positive for Coronavirus Disease 2019.一位新型冠状病毒肺炎检测持续呈阳性的医生的视角。
Clin Infect Dis. 2021 Apr 8;72(7):1290-1291. doi: 10.1093/cid/ciaa551.
8
Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19.有症状的COVID-19感染后，癌症患者体内SARS-CoV-2抗体的检测率低于医护人员。
Ann Oncol. 2020 Aug;31(8):1087-1088. doi: 10.1016/j.annonc.2020.04.475. Epub 2020 May 1.